PNV - Chart, page-16653

BIG PHARMA with their established, deeply penetrative global marketing infrastructure, would not need to worry about the huge costs of setting up marketing infrastructure that PNV has and which it is being punished for with stock price, but would concentrate on growth in uptake, efficacy of products ( productions cost advantages from competitors , ease of use, competitive advantage with infection and other risks and possible uses) , global market potential and size, including reputational feedback and goodwill from specialists and major hospitals, As David details in his recent interview ( https://stocksdownunder.com/video/polynovo-interview/ ), the synergistic benefits with a company like J&J creates a different game plan. We need the next three months of new customers and sales to be good to increase the price before a takeover offer which if coming could be made by end of 2023. As much as I would love to see the company being a huge aussie success story the pragmatist in me has strongly factored this scenario in.